Ann: Trading Halt, page-32

First 32 Last

Share
Profile

Follow
HeavyT

481 Posts.

96

10/12/20

10:30

Post #: 49476619
Share

Originally posted by Harry1960: ↑

What is a capital raising?
Put simply, capital raising is a mechanism for an ASX company to raise money.

Companies typically have 3 options if they are in need of more capital.
The first is to sell assets.
The second is to borrow money in the form of issuing bonds (which is the company equivalent of an individual taking out a bank loan).
And the third is a capital raise.

Capital raising typically involves offering new shares (representing ownership of the business) to investors in an off-market deal. Normally, a company’s shares remain relatively fixed at a certain volume.

That way supply and demand for the fixed pool of shares enables the market to set what we call the share price of said company.

But if a company needs extra money, it will offer new shares to investors at a fixed price (usually at a small discount to the shares’ recent ASX price).

This can be an easy way to raise extra dough for the company if times are tough (like they are right now).But it’s usually the method of last resort for cash-strapped companies that (for whatever reason) can’t sell assets or go to the bond markets.

Expand

so by that logic you believe companies shouldn't raise money? if thats the case you probably shouldn't be investing.

selling bonds for a smallcap like this is a non starter, you get yourself in all sorts of strife with covenants etc - long term pain
selling assets? non starter
CR is a quick and does the job. short term pain..

companies of all sizes do CR Woodside, BHP RIO the list is endless.

MGV Price at posting: 42.5¢ Sentiment: Buy Disclosure: Held
8 Upvote

1 Great analysis

Reply

Top Stories

IRE

Iress runs 'hot' for Wealth Within's stock tips

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Failure to report prompts ASX to impose multiple company suspensions